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Abstract
Diabetes is characterized by a dysregulation of glucose homeostasis and platelets from patients with diabetes are
known to be hyper-reactive and contribute to the accelerated development of vascular diseases. Since many of the
deleterious effects of glucose have been attributed to its metabolite methylgyloxal (MG) rather than to hyperglycemia
itself,  the  aim  of  the  present  study  was  to  characterize  the  effects  of  MG  on  platelet  function.  Washed  human
platelets were pre-incubated for 15 min with MG and platelet aggregation, adhesion on matrix-coated slides and
signaling (Western blot) were assessed ex vivo. In vivo, the effect of MG on thrombus formation was determined
using the FeCl3-induced carotid artery injury model. MG potentiated thrombin-induced platelet aggregation and dense
granule  release,  but  inhibited  platelet  spreading  on  fibronectin  and  collagen.  In  vivo,  MG  accelerated  thrombus
formation but decreased thrombus stability. At the molecular level, MG increased intracellular Ca2+ and activated
classical PKCs at the same time as inhibiting PI3K/Akt and the β3-integrin outside-in signaling. In conclusion, these
findings indicate that the enhanced MG concentration measured in diabetic patients can directly contribute to the
platelet dysfunction associated with diabetes characterized by hyperaggregability and reduced thrombus stability.
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Introduction
Diabetes  mellitus  is  associated  with  the  accelerated
development of cardiovascular diseases which are the primary
cause of morbidity and mortality in patients. Indeed, it is well
accepted  that  the  pathogenesis  and  progression  of  the
vascular  complications  of  diabetes  are  characterized  by  the
development  of  endothelial  dysfunction  and  an  alteration  in
platelet  function.  Although  a  dysregulation  of  glucose
homeostasis  is  one  of  the  hallmarks  of  diabetes,  the
intracellular  mechanism  linking  hyperglycemia  and  platelet
hyperreactivity are not fully understood.
One  consequence  of  elevated  plasma  glucose
concentrations  is  the  increased  formation  of  methylglyoxal
(MG)  [1];  a  highly  reactive  dicarbonyl  metabolite;  that  is
generated endogenously by the nonenzymatic degradation of
the glycolytic intermediates, dihydroxyacetone phosphate and
glyceraldehyde-3-phosphate  [2].  Normally,  plasma  levels  of
MG are maintained at a low levels by the glyoxalase I [3,1],
however, this pathway is impaired in diabetes [4], which results
in the accumulation of MG [5,6]. Most of the deleterious effects
of  MG  have  been  attributed  to  the  formation  of  advanced
glycation end-products (AGEs) and the subsequent activation
of the AGE receptor; RAGE, which then initiates the vascular
and neuronal complications of diabetes. However, MG can also
exert effects that are independent of the AGE-RAGE pathway.
For  example,  MG  was  found  to  depolarize  sensory  neurons
and  induce  the  post-translational  modification  of  the  voltage-
gated sodium channel Na  v1.8 thus resulting in an increased
electrical excitability of nociceptive neurons [7]. Moreover, MG
has  been  reported  to  enhance  the  formation  of  neutrophil-
platelet  aggregates  [8]  and  to  increase  platelet  hydrogen
peroxide  formation  [9].  This  study  set  out  to  determine  the
effects of MG on platelet function in vitro and in vivo and to
determine the molecular pathways targeted by the metabolite.
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Reagents
Type I collagen, fibronectin, and the anti-PKCα and PKC-β
antibodies were from BD transduction laboratories (Heidelberg,
Germany).  Thrombin  was  from  Hemochrom  Diagnostica
(Essen,  Germany),  U46619  was  from  Cayman  Chemical
(Biomol,  Hamburg,  Germany).  The  anti-Ser19-MLC20,  anti-
total Akt and anti-phospho Ser473- Akt antibodies were from
Cell Signaling (New England Biolabs, Frankfurt, Germany), the
anti-Tyr747  β3  integrin  antibody  was  from  Invitrogen
(Karlsruhe,  Germany),  the  anti-β3  integrin  antibody  from
Chemicon  (Hofheim,  Germany)  and  Ro-318220
(bisindolylmaleimide IX) was from Alexis (Lörrach, Germany).
All other compounds and antibodies were from Sigma-Aldrich
(Steinheim, Germany).
Preparation of glycated albumin.  Glycated-human serum
albumin (G-HSA) was prepared by incubating native HSA with
250 mmol/L D-glucose at 37°C for 4 weeks in Ca2+-Mg2+-free
phosphate buffered saline (PBS) containing protease inhibitors
and antibiotics. Control-HSA was processed the same way in
the absence of glucose. At the end of the incubation period, the
solutions were dialyzed against PBS at 4°C for 24 h to remove
unincorporated  glucose,  and/or  antibiotics  and  then  sterile
filtered.
Healthy donors and diabetic patients
A total of 19 patients (8 women, 11 men; mean age 41±7.3
years; hemoglobin (Hb) A1c over 7.4%, fasting plasma glucose
8.4±0.8 mmol/L and fasting plasma insulin 18.5 ±10.9 mU/L)
with  type  2  diabetes  mellitus  attending  the  clinic  for  routine
control visits were included in the present study. All patients
were  treated  with  insulin  alone  or  in  combination  with
metformin. Nondiabetic, age-matched subjects (17 women, 23
men;  mean  age  34.9±8.3  years;  HbA1c  5.3±0.56%;  fasting
plasma  glucose  5.2±0.2  mmol/L  and  fasting  plasma  insulin
8.17±6.4 mU/L) who had not taken any medication known to
interfere with platelet aggregation for at least 10 days before
the experiment served as the control group.
Ethics statement
The study protocol was approved by the ethics committee of
the  Goethe  University  Hospital  (No.  E  61/09  geschäfts  Nr
86/09)  and  all  of  the  participants  gave  written  informed
consent.
Animals
C57BL/6 mice (6-8 weeks old) from Charles River (Sulzfeld,
Germany) were used for the present study. Mice were housed
in conditions that conform to the Guide for the Care and Use of
Laboratory Animals published by the U.S. National Institutes of
Health (NIH publication no. 85-23). Both the University Animal
Care  Committees  and  the  Federal  Authorities  for  Animal
Research,  Regierungspräsidium  Darmstadt  (Hessen,
Germany; F28/44) approved the study protocol.
Platelet isolation
Human  platelets  were  obtained  by  centrifugation  (900g,
7  minutes)  of  platelet-rich  plasma,  as  described  [10].  The
resulting  pellet  was  washed  in  Ca2+-free  HEPES  buffer
(mmol/L:  NaCl,  136;  KCl,  2.6;  MgCl2,  0.93;  NaH2PO4,  3.26;
glucose, 5.5; HEPES, 3.7; pH 7.4 at 37°C) and samples were
either  lysed  for  Western  Blot  analysis,  or  resuspended  in
HEPES  buffer  to  a  density  of  4x108  platelets/mL  for  the
measurement  of  intracellular  Ca2+  or  platelet  aggregation  as
outlined [11].
Immunoblotting
Washed human platelets in suspension or platelets adherent
on fibronectin or collagen were solubilized in Triton X-100 lysis
buffer  and  Triton  X-100  soluble  proteins  were  separated  by
SDS-PAGE and subjected to Western blotting and visualized
by  enhanced  chemiluminescence  using  a  commercially
available  kit  (Amersham,  Freiburg,  Germany),  as  described
[10].
Platelet aggregation
Aggregation  of  washed  human  platelets  or  platelet-rich
plasma (4x108 platelets/mL) was measured using an 8-channel
aggregometer (PAP8, Mölab, Germany).
Calcium measurements
Changes  in  [Ca2+]i  were  determined  by  measuring  fura-2
fluorescence. Platelets were loaded with fura-2/AM (5 µmol/L, 1
hour,  37°C)  and  [Ca2+]i  was  determined  fluorometrically  by
continuous  rapid  alternating  excitation  from  dual
monochromators set at 340 and 380 nm (Deltascan, Photon
Technology) as described [11].
ATP measurement
The  release  of  ATP  was  determined  using  a  luciferin/
luciferase ATP kit (Enliten® ATP assay system; Promega) as
described [10].
Methylglyoxal measurement
Platelet-poor plasma (PRP) from healthy donors and diabetic
patients was separated from whole blood and stored at -80°C
until  analysis.  MG  concentration  was  measured  using  a
commercially  available  ELISA  kit  (MBS704102  from
MyBiosource).
P-selectin expression
Washed human platelets were incubated with either solvent
or MG for 15 minutes and then stimulated with either solvent or
the thrombin receptor agonist (TRAP, 10 µM, 5 minutes). After
stimulation, platelets were fixed with formalin (2% in PBS v/v,
15 minutes), washed and incubated with FITC-conjugated anti-
P-selectin  Ab,  or  control  mouse  IgG  for  15  minutes  at  room
temperature.  After  washing  surface  expression  of  P-selectin
was  analyzed  using  a  FACSCalibur  flow  cytometer  (BD
Biosciences).
Methylglyoxal in Platelet Signaling and Function
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Static  adhesion  assays  were  performed  as  described  [12].
Briefly,  washed  human  platelets  were  incubated  with  either
solvent or MG (1 mmol/L) in the absence or in the presence of
different stimuli. Platelet suspensions (5x104 platelets/µL) were
seeded  on  glass  slides  (µ-Slide  8  well,  ibidi,  Martinsried,
Germany),  coated  with  either  fibronectin  (100  µg/ml)  or
collagen  (1.8  ng/ml)  and  incubated  at  37°C  for  60  minutes.
Nonadherent platelets were removed by washing and adherent
and spread platelets were fixed. Images were captured by a
AxioCam MRm on a Cell Observer microscope (Zeiss, Jena,
Germany) and analyzed using the imaging software AxioVision
4.8 (Zeiss, Jena, Germany).
In vivo thrombosis formation
Mice  were  anesthetized  by  intraperitoneal  injection  of
ketamine  and  xylazine  and  placed  on  a  heated  mat.  MG  (1
mmol/L) was injected into the jugular vein and the fluorescent
dye  3,3’-dihexyloxacarbocyanine  iodide  (DIOC6;  Ivitrogen,
Darmstadt,  Germany)  was  also  administered  (5  µL  of  a  100
µmol/L  solution/g  body  weight)  after  25  minutes  to  allow
visualization of the thrombus. Thereafter, a segment of the right
carotid  artery  was  exposed  and  injury  was  induced  by  the
topical application of FeCl3 for 2 minutes (Whatmann paper 1
mm2 soaked with 0.2 µL of 10% FeCl3) as described [12]. The
artery was then rinsed with saline and thrombus formation was
monitored for 30 minutes by placing the carotid artery under a
fluorescence microscope equipped with a camera (AxioScope,
Carl Zeiss, Jena, Germany). Fluorescent images were acquired
sequentially  (1  image/second)  and  thrombus  size  was
quantified using AxioVision 4.7 imaging software (Carl Zeiss).
Statistical analysis
Data  are  expressed  as  mean  ±  SEM  and  statistical
evaluation was performed using Student’s t test for unpaired
data or one-way analysis of variance (ANOVA) followed by a
Bonferroni  t  test  where  appropriate  using  Prism  software
(GraphPad).  Values  of  P<0.05  were  considered  statistically
significant.
Results
Effects of methylglyoxal on platelet aggregation
induced by thrombin and collagen
MG was measured in PRP from 10 healthy subjects and 10
diabetic patients using an ELISA kit. We were unable to detect
MG in any of the samples studied. However, given that other
methods measured millimolar concentration of MG in plasma
from patients with type 2 diabetes, we chose to use 1 mmol/L
MG  for  short-time  stimulation  in  order  to  simulate  the
postprandial burst of MG encountered in diabetic patients.
The addition of MG (1 mmol/L) to washed human platelets
induced a small but significant aggregation (10.1±0.9% of the
maximum  response  to  thrombin;  n=8,  P<0.01).  D-mannitol
failed to affect aggregation indicating that the response to MG
could  not  simply  be  attributed  to  an  osmotic  change  (Figure
S1). When added prior (15 minutes) to other platelet agonists,
MG  potentiated  the  aggregation  to  thrombin  and  collagen
(Figure 1A& B). Interestingly, when the response to MG was
assessed  in  PRP,  we  found  it  enhanced  the  response  to
thrombin in samples from healthy donors but had no effect on
samples  from  diabetic  patients  (Figure  1C).  In  order  to
determine  the  consequences  of  RAGE  activation  on  platelet
responses, washed human platelets were treated with glycated
human serum albumin (G-HSA). The AGE did not reproduce
the  effects  of  MG  i.e.  did  not  potentiate  the  aggregation
induced  by  a  low  concentration  of  thrombin.  However,  high
concentrations  of  G-HSA  tended  to  inhibit  thrombin-induced
aggregation (Figure 1D). An effect we also observed with the
native HSA and may be related to the albumin itself rather than
the glycation (data not shown).
Effects of MG on Ca2+ and Platelet Degranulation
Given that the MG-induced increase in aggregation may be
related  to  altered  Ca2+  signaling  we  assessed  platelet  Ca2+
responses  to  thrombin  in  fura-2-loaded  washed  human
platelets. Consistent with the small effect on aggregation, MG
elicited a small (68±4 nmol/L; n=6, P<0.01) but sustained (over
15 minutes) increase in Ca2+ over basal levels. However, MG
did not significantly alter the Ca2+ response to thrombin (Figure
2A). Given that an increase in [Ca2+]i is prerequisite for platelet
Figure  1.    Effect  of  MG  on  platelet
aggregation.  Aggregation of washed human platelets treated
with either solvent (CTL) or methylglyoxal (MG, 1 mmol/L, 15
minutes) prior to the stimulation with either (a) thrombin or (b)
collagen.  (c)  Thrombin-induced  aggregation  of  platelet  rich
plasma  from  healthy  (CTL)  or  diabetic  patients  (Dia)  in  the
absence or in the presence of solvent or MG. (d) Aggregation
of washed human platelets treated with either solvent (CTL),
methylglyoxal (MG, 1 mmol/L, 15 minutes) or glycated human
serum albumin (G-HAS, 40 and 300 µg, 15 minutes) prior to
the stimulation with thrombin. The graphs summarise the data
from at least 6 different individuals; *P<0.05, **P<0.01 versus
CTL.
doi: 10.1371/journal.pone.0074401.g001
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induced by low concentrations of agonists, we assessed the
effects of MG on the secretion of dense and α-granules. MG
alone did not affect the release of ATP but it did enhance the
release  of  ATP  induced  by  thrombin  (Figure  2B).  MG  also
failed to increase the surface expression of P-selectin or affect
the responses to the thrombin receptor agonist TRAP (Figure
2C) suggesting that MG did not influence α-granule secretion.
Methylglyoxal stimulates the membrane translocation
of PKCα/β and the phosphorylation of MLC-20
Given the central role played by protein kinase C (PKC) in
platelet  activation  [13]  and  the  fact  that  PKC  activity  is
enhanced in diabetic platelets [14], we determined whether the
effects of MG could be linked to a change in PKC activity.
The activation of PKC was initially assessed by determining
its  translocation  between  the  cytosol  and  membrane.  Using
specific antibodies we found that MG induced the membrane
translocation  of  PKCα/β  and  potentiated  the  response  to
thrombin  (Figure  3A).  Protein  kinase  C  α/β  are  of  particular
interest  in  platelets  since  they  phosphorylate  and  inhibit  the
myosin  light  chain  (MLC)  phosphatase,  and  regulate  the
phosphorylation  of  MLC-20;  which  is  important  for  the
cytoskeletal  reorganization  that  takes  place  during  platelet
aggregation  and  adhesion.  We  found  that  MG  alone
significantly enhanced the phosphorylation of MLC20 and that
this  effect  was  sensitive  to  PKC  inhibition  (Figure  3B).
Moreover,  MG  potentiated  the  thrombin-induced  increase  in
MLC20  phosphorylation  (Figure  3C).  Since  Rho  kinase  can
also regulate MLC20 phosphorylation we tested the effect of
Figure  2.    Effect  of  MG  on  platelet  [Ca2+]i  and
degranulation.    (a)  Increase  in  [Ca2+]i  measured  in  washed
human  platelets  treated  with  either  solvent  (CTL)  or
methylglyoxal  (MG,  1  mmol/L,  15  minutes)  prior  to  the
stimulation with thrombin. (b) Effect of MG pre-treatment on the
thrombin  (0.03U/ml)-induced  release  of  ATP  and  (c)  on  the
TRAP-induced  surface  expression  of  P-selectin.  The  graphs
summarise  the  data  from  at  least  6  different  individuals;
*P<0.05, **P<0.01 versus CTL.
doi: 10.1371/journal.pone.0074401.g002
the  Rho  kinase  inhibitor  Y27632  on  MG-induced  MLC20
phosphorylation  and  found  that  Y27632  did  not  affect  the
response to MG while it inhibited the response to agonists such
as  thrombin  and  thromboxane  A2  (Figure  S2).  The  PKC
inhibitor,  R0-318220  (300  nmol/L)  reversed  the  MG-induced
increase in thrombin-induced platelet aggregation (Figure 3D).
Effect of MG on platelet adhesion, spreading and
thrombus stability
When exposed to the extracellular matrix, platelets adhere,
develop  filopodia  and  then  spread  [15].  MG  significantly
enhanced the number of platelets that adhered to both collagen
and  fibronectin  but  subsequently  inhibited  platelet  spreading
even after 60 minutes of incubation (Figure 4A).
Figure 3.  Effect of MG on PKC activation.  (a) Membrane
translocation  of  PKCα  and  β  in  washed  human  platelets
stimulated  with  either  methylglyoxal  (MG,  1  mmol/L,  15
minutes) or thrombin (0.03U/ml) alone or in combination. (b)
Effect of methylglyoxal (MG, 1 mmol/L, 15 and 30 minutes) on
the  phosphorylation  of  MLC20  in  the  absence  or  in  the
presence  of  the  PKC  inhibitor  Ro-318820  (Ro,  300  nM,  30
minutes).  (c)  Effect  of  MG  on  thrombin-induced
phosphorylation  of  MLC20.  (d)  Effect  of  Ro-318220  on  the
thrombin-induced  aggregation  of  washed  human  platelets
treated or not with MG. The graphs summarise the data from
6-8 different experiments; *P<0.05, **P<0.01 versus CTL and #
P<0.05, # # P<0.01 versus agonists.
doi: 10.1371/journal.pone.0074401.g003
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injury  is  essential  for  hemostasis  and  thrombus  stabilization,
we next investigated the effect of MG on thrombus formation in
vivo after FeCl3-induced injury of the carotid artery. Formation
of the initial thrombus was not significantly different in vehicle
and MG-treated mice but the thrombus was larger in the MG-
treated  group  (Figure  4B)  and  was  also  less  stable.  Indeed,
emboli  frequently  detached  from  the  primary  thrombus  (see
squares  in  Figure  4B).  MG-treated  mice  also  have  a
significantly shorter bleeding time (46.4±11.55s) compared to
untreated control mice (151.8±30.26s). Moreover, re-bleeding
was observed in 50% of the MG-treated mice confirming the
formation of unstable clot.
Figure 4.  Effect of MG on platelet adhesion, spreading and
in vivo thrombus formation.  (a) Representative pictures and
(b)  quantification  of  adherent  and  spread  washed  human
platelets  (to  fibronectin  (Fn)-  or  collagen  (coll)-coated  slides)
pre-treated with either solvent (CTL) or methylglyoxal (MG, 1
mmol/L, 15 minutes). (c) Representative pictures (upper panel)
and  quantification  (lower  graphs)  of  the  effect  of  in  vivo
treatment of healthy mice with MG (1 mmol/L, 15 minutes) on
thrombus size and time to peak after FeCl3-induced injury of
carotid artery. The graphs summarize data obtained in platelets
from 12 subjects or 6 animals per group; *P<0.05, ***P<0.001,
versus CTL.
doi: 10.1371/journal.pone.0074401.g004
MG inhibits the phosphorylation of β3-integrin
Platelet  adhesion  leads  to  the  tyrosine  phosphorylation  of
αIIbβ3  integrin  which  transmits  the  outside  in  signal  that  is
important  for  platelet  spreading  and  thrombus  stabilization.
Given that the latter were impaired by MG, we assessed the
effects of the compound on β3 integrin phosphorylation. The
adhesion  of  human  platelets  to  fibronectin  or  collagen
significantly  enhanced  β3  integrin  tyrosine  phosphorylation
(Figure 5A), an effect that was not observed in platelets pre-
treated  with  MG.  These  effects  were  not  dependent  on
adhesion  per  se  as  MG  also  attenuated  the  tyrosine
phosphorylation of β3 integrin in platelet suspensions treated
with thrombin (Figure 5B). MG did not affect either the basal or
the  agonist-induced  increase  in  the  expression  of  active  β3
integrin  on  platelet  surface,  suggesting  that  MG  did  not  act
upstream of the integrin inside-out signaling (Figure S3).
The phosphatidylinositol 3-kinase (PI3K) plays an important
role in regulating the function of integrin αIIbβ3 [16], therefore,
we  assessed  the  effects  of  MG  on  the  agonist-induced
phosphorylation of the PI3K downstream target Akt. While Akt
phosphorylation  (on  Ser473)  was  enhanced  in  platelets
adherent on collagen and fibronectin, pre-incubation with MG
attenuated  Akt  phosphorylation  (Figure  5C).  Given  that  PI3K
can act upstream as well as downstream of the integrin αIIbβ3
outside-in signaling we tested the effects of the PI3K inhibitor
wortmannin  on  β3  integrin  phosphorylation.  Wortmannin
significantly  inhibited  fibronectin  and  collagen-induced
phosphorylation of Akt and β3 integrin (Figure 5D) suggesting
that the β3 integrin activation is downstream of PI3K.
Discussion
The  results  of  the  present  investigation  indicate  that  MG
exerts  a  dual  effect  on  platelet  activation:  a  pro-aggregatory
and pro-thrombotic effect linked to an increase in [Ca2+]i, and
activation  of  classical  PKC  pathway,  and  an  anti-spreading
effect that involves the inhibition of PI3K/Akt pathway and the
β3 integrin outside-in signaling.
While the deleterious effects of MG have been mostly linked
to  its  rather  slow  formation  and  activation  of  RAGE  [17]  the
results of the present study indicate that MG can acutely alter
platelet reactivity and function. Such an acute effect can be a
direct  consequence  of  a  rapid  increase  in  blood  MG
concentration, such as that after a meal or during the so-called
hyperglycemic spikes. Certainly, the hyperglycemic spikes that
are often observed in patients with poorly managed diabetes
have  been  shown  to  enhance  the  risk  of  developing
cardiovascular  complications.  Moreover,  acute  hyperglycemia
has  been  reported  to  enhance  shear  stress-induced  platelet
activation in patients with type II diabetes [18]. Depending on
the method used to determine MG levels, its concentration in
plasma has been reported to be significantly higher (up to 6
times)  in  patients  with  type  2  diabetes  compared  to  healthy
donors.  For  example,  0.4  mM  MG  has  been  measured  in
diabetic plasma using GC-MS and mM levels can be reached
postprandially [5]. Our failure to measure MG in plasma using a
commercially  available  ELISA  kit  suggests  that  either  this
assay  method  is  inappropriate  for  the  detection  of  MG  in
Methylglyoxal in Platelet Signaling and Function
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Given that the intracellular concentration of MG is thought to be
higher  than  the  circulating  levels  it  is  also  very  likely  that
platelets from healthy vs diabetic patients mainly differ on their
intracellular  MG  levels.  In  our  study,  the  use  of  1  mM
concentration  of  MG  for  short-time  stimulation  simulates  the
postprandial burst of MG encountered in diabetic patients. This
concentration  is  close  to  the  pathophysiologically  relevant
range and has frequently been used by others investigating the
biological  actions  of  MG  [19,20].  Our  finding  that  MG  was
unable to affect the aggregation of PRP from diabetic patients
may be explained by the fact that diabetic platelets which are
permanently  exposed  to  high  plasma  and/or  intracellular
Figure  5.    Effect  of  MG  on  the  phosphorylation  of  β3
integrin  and  Akt.    (a)  Effect  of  MG  (MG,  1  mmol/L,  15
minutes)  on  fibronectin  (Fn)  and  collagen  (coll)-induced
tyrosine phosphorylation of β3 integrin (Tyr747). (b) Effect of
MG on thrombin -induced tyrosine phosphorylation (Tyr747) of
β3  integrin  in  washed  human  platelets.  (c)  Effect  of  MG  on
fibronectin (Fn) and collagen (coll)-induced phosphorylation of
Akt  (Ser  473).  (d)  Effect  of  wortmannin  (Wt,  20  nmol/L,  30
minutes)  on  fibronectin  (Fn)  and  collagen  (coll)-induced
phosphorylation of β3 integrin (Tyr747) and Akt (Ser 473). The
graphs  summarise  the  data  from  6  different  experiments;
*P<0.05,  ***P<0.001  versus  sol  or  CTL  and  #  P<0.05,  #  #  #
P<0.001 versus agonists.
doi: 10.1371/journal.pone.0074401.g005
concentration  of  MG  in  vivo  are  hyperreactive  and  do  not
further react to the addition of MG in vitro.
Regarding its mechanisms of action, we found that MG on its
own  was  able  to  enhance  platelet  [Ca2+]i,  activate  PKC  and
enhance the phosphorylation of MLC20. The first steps in this
process e.g. binding to an extracellular or intracellular mediator
are currently unknown. However, since the acute application of
G-HSA failed to reproduce the effects of MG the involvement of
RAGE seems unlikely. Another possibility is that MG may bind
to a non-RAGE receptor to mediate its effects as it has been
characterized  as  a  GABAA  receptor  agonist  [21]  and  can
directly affect the function of the voltage-gated sodium channel
Na  v1.8  [7].  An  extracellular  receptor  may,  however,  not  be
required as MG is membrane permeable [19,22]. Finally, the
fact that the potentiating effect of MG was only evident at low
concentrations  of  agonists  and  was  surmounted  by  high
concentrations  of  agonists  points  towards  a  competitive
interaction  of  MG  with  a  common  intracellular  signaling
pathway.
The  effect  of  MG  on  platelet  [Ca2+]i  was  paralleled  by  the
activation  of  classical  PKCs,  and  the  phosphorylation  of
MLC20. Phosphorylation of MLC20 is thought to be one of the
primary steps in the activation of actomyosin contractile events,
important  for  platelet  shape  change  and  granule  secretion
[23,24].  Although  calcium-  and  calmodulin-dependent  myosin
light chain kinase (MLCK) has been initially considered to be
the  primary  regulator  of  MLC20  phosphorylation,  it  is  well
accepted  to  be  regulated  by  the  inhibition  of  the  MLC20
phosphatase.  The  latter  involves  both  the  Rho  kinase  and
PKCs. We were able to demonstrate that contrary to agonist-
induced  MLC20  phosphorylation,  which  was  predominantly
Rho-kinase  dependent,  the  MG-induced  effect  primarly
involves PKC.
The release of granule contents is an important step in the
transmission and perpetuation of signaling between platelets.
Given that it is tightly regulated by PKC [13] it was logic to look
at  the  effect  of  MG  on  platelet  degranulation.  Interestingly,
despite its ability to activate PKC, MG did not directly affect the
degranulation of either dense or α-granules, but enhanced the
thrombin-induced secretion of dense granule contents. Exactly
why a substance that clearly affects PKC activity had no effect
on degranulation is unclear but the level of PKC activation may
have  been  below  the  threshold  required  to  promote  platelet
degranulation.
Perhaps the most impressive effect of MG was its ability to
prevent the spreading of platelets on collagen and fibronectin.
Platelet  activation  with  agonists  such  as  thrombin  or  via  the
binding of β1 integrin to matrices during platelet adhesion leads
to the initiation of common signaling events that finally result in
a conformational change and αIIbβ3 integrin activation (inside-
out signaling). The active integrin can then bind fibrinogen and
transmit an outside-in signaling resulting in platelet spreading
and thrombus stabilization [25]. How could MG interfere with
the  mechanisms  involved  in  integrin  outside-in  signaling?  It
clearly  prevented  the  tyrosine  phosphorylation  of  β3  integrin
and  this  effect  could  be  attributed  to  the  activation  of  the
PI3K/Akt  cascade  which  is  essential  for  platelet  spreading
[26,27,28,29] as well as for the phosphorylation and activation
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initially reported in pancreatic beta cells [22] where it has been
suggested to be, at least in part, linked to GSK-3 activation.
Whether  the  effect  of  MG  in  platelets  also  involve  GSK-3
activation is however unclear. PI3K is a key enzyme in platelet
activation which can act upstream and downstream of the β3
integrin.  Our  finding  that  despite  the  inhibition  of  PI3K,  MG
failed to affect the thrombin-induced expression of active β3 on
the platelet surface (inside-out signaling) suggests that the MG-
mediated PI3K inhibition is likely to be downstream of integrin
inside-out  signaling.  Given  that  the  activation  of  PI3K  by  β3
integrin outside-in signaling has been reported to be important
for  thrombus  stabilization  [31,32],  it  was  expected  that  MG
which interferes with PI3K and platelet spreading would have
significant consequences for thrombus formation and stability.
Indeed,  it  was  exactly  what  was  observed  in  vivo  on  MG-
treated mice which developed large but unstable thrombin. A
phenomenon similar to what we previously reported in diabetic
mice  [33].  However,  given  that  diabetes  is  associated  with
increased circulating levels of insulin which is known to be a
potent  activator  of  the  PI3K/Akt  pathway,  the  diabetes-
associated changes in platelet function are likely the result of a
complex interplay between insulin-induced hyperactivation and
MG-induced inhibition of the Akt pathway.
Taken together, the present study shows that MG, by directly
increasing  platelet  aggregability  and  decreasing  thrombus
stability,  induces  a  pro-thrombotic  phenotype  in  mice.
Furthermore, the finding of the present study provides further
evidence  for  the  importance  of  MG  in  the  pathogenesis  of
thrombotic complications encountered in diabetes. Given that
an increased circulating MG has been also reported in different
pathological  conditions  [34],  understanding  the  molecular
mechanisms of action of MG may help developing a targeted
therapy to fight against its deleterious effect.
Supporting Information
Figure  S1.    Effect  of  mannitol  on  the  thrombin-induced
aggregation. Washed human platelets were treated with either
solvent (CTL) or mannitol (1 mmol/L, 15 minutes) prior to the
stimulation with thrombin. The graphs summarise the data from
at least 5 different individuals.
(TIF)
Figure S2.  Effect of Ro-318820 (Ro, 300 nM, 30 minutes)
and Y27632 (Y27, 10 µM, 30 minutes) on the MG, thrombin
and  U46-induced  phosphorylation  of  MLC20  in  washed
human  platelets.  Identical  results  were  obtained  in  4
additional experiments.
(TIF)
Figure S3.  Effect of MG on the surface expression of the
active β3 integrin. Washed human platelets were incubated
with either solvent or MG (1 mmol/L, 15 minutes) prior to the
stimulation with either the thrombin receptor activating peptide
(TRAP)  or  the  thromboxane  A2  analogue  (U46619)  and  the
surface expression of active β3 integrin was detected by flow
cytometry.  The  graphs  summarise  the  data  from  at  least  5
different individuals. *P<0.05 versus CTL.
(TIF)
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